Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (151-160 of 350) with videos related to

Pageof 35
Sort By:
Journal of Clinical Gastroenterology|October 13, 2022
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Achuthan Aruljothy, et al.
Scandinavian Journal of Gastroenterology|March 18, 2020
Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapySofie Coenen, Egon Nijns, Ellen Weyts, et al.
Journal of Crohn'S & Colitis|January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative ColitisIris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
European Journal of Gastroenterology & Hepatology|September 8, 2016
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatmentLucas Wauters, Thomas Billiet, Konstantinos Papamichael, et al.
Journal of Clinical Gastroenterology|June 24, 2025
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion StudyMichael Scharl, Britt Christensen, Brian Bressler, et al.
Journal of Crohn'S & Colitis|March 6, 2024
Disease Acceptance, but not Perceived Control, is Uniquely Associated with Inflammatory Bowel Disease-related DisabilityAnouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, et al.
Inflammatory Bowel Diseases|August 27, 2015
Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor TherapyZhe Li, Séverine Vermeire, Dominique Bullens, et al.
United European Gastroenterology Journal|August 8, 2018
Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter studyTriana Lobatón, Talat Bessissow, Alexandra Ruiz-Cerulla, et al.
International Journal of Molecular Sciences|January 8, 2023
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative ColitisSara Deleu, Kaline Arnauts, Lowie Deprez, et al.
European Journal of Gastroenterology & Hepatology|May 1, 2026
Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion studyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 35

Showing results (151-160 of 350) with videos related to

Sort By:
Pageof 35
Journal of Clinical Gastroenterology|October 13, 2022
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's DiseaseNeeraj Narula, Emily C L Wong, Achuthan Aruljothy, et al.
Scandinavian Journal of Gastroenterology|March 18, 2020
Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapySofie Coenen, Egon Nijns, Ellen Weyts, et al.
Journal of Crohn'S & Colitis|January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative ColitisIris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
European Journal of Gastroenterology & Hepatology|September 8, 2016
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatmentLucas Wauters, Thomas Billiet, Konstantinos Papamichael, et al.
Journal of Clinical Gastroenterology|June 24, 2025
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion StudyMichael Scharl, Britt Christensen, Brian Bressler, et al.
Journal of Crohn'S & Colitis|March 6, 2024
Disease Acceptance, but not Perceived Control, is Uniquely Associated with Inflammatory Bowel Disease-related DisabilityAnouk Teugels, Ilse van den Eijnden, Bep Keersmaekers, et al.
Inflammatory Bowel Diseases|August 27, 2015
Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor TherapyZhe Li, Séverine Vermeire, Dominique Bullens, et al.
United European Gastroenterology Journal|August 8, 2018
Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter studyTriana Lobatón, Talat Bessissow, Alexandra Ruiz-Cerulla, et al.
International Journal of Molecular Sciences|January 8, 2023
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative ColitisSara Deleu, Kaline Arnauts, Lowie Deprez, et al.
European Journal of Gastroenterology & Hepatology|May 1, 2026
Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion studyMarc Ferrante, Britt Christensen, Brian Bressler, et al.
Pageof 35